sEH-IN-26
sEH-IN-26 is a urea structure-based soluble epoxide hydrolase (sEH) inhibitor with selectivity for mammalian cytosolic and peroxisomal sEH. sEH-IN-26 can be used for the research of inflammation and epoxide hydrolase-related diseases.
For research use only. We do not sell to patients.
- CAS No.: 2222-58-4
- Formula: C14H26N2O
- Molecular Weight:238.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
sEH |
In Vitro
sEH-IN-26 (compound 57) potently inhibits soluble epoxide hydrolase, with an IC50 of 0.06 μM against mouse sEH and 0.16 μM against human sEH. It shows almost no inhibitory effect on rat microsomal mEH, with an IC50 greater than 500 μM, and exhibits extremely high subtype selectivity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2222-58-4
-
Molecular Weight 238.37
-
Formula C14H26N2O
-
SMILES
O=C(NC1CCCCC1)NCC2CCCCC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)